

Richard A Hansen, Rph, Fapha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4587538/publications.pdf>

Version: 2024-02-01

112
papers

3,876
citations

147801
31
h-index

133252
59
g-index

112
all docs

112
docs citations

112
times ranked

5697
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of cognitive impairment on survival and medication adherence among older women with breast cancer. <i>Breast Cancer</i> , 2021, 28, 277-288.	2.9	6
2	An Examination of Prescribing Responsibilities between Psychiatrists and Primary Care Providers. <i>Psychiatric Quarterly</i> , 2021, 92, 587-600.	2.1	1
3	The association of continuity of care and risk of mortality in breast cancer patients with cardiometabolic comorbidities. <i>Journal of Psychosocial Oncology</i> , 2021, , 1-15.	1.2	2
4	Primary Care Physiciansâ€™, Psychiatristsâ€™, and Oncologistsâ€™ Coordination While Prescribing Medications for Patients With Multiple Chronic Conditions. <i>Journal of Patient Safety</i> , 2021, Publish Ahead of Print, e424-e430.	1.7	0
5	Understanding authorized genericsâ€™ A review of the published clinical data. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1489-1497.	1.5	2
6	Perceived appropriateness of medication adherence incentives. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 772-778.	0.9	1
7	Disparities in Cognitive Impairment With Anticholinergic Drug Use. <i>Neurology: Clinical Practice</i> , 2021, 11, e277-e286.	1.6	1
8	How comfortable are primary care physicians and oncologists prescribing medications for comorbidities in patients with cancer?. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1087-1094.	3.0	7
9	Healthcare provider opinions about a generic drug educational newsletter. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1228-1236.	3.0	3
10	The association between antidepressants use and development of cognitive impairment among older women diagnosed with breast cancer. <i>European Geriatric Medicine</i> , 2020, 11, 1017-1026.	2.8	0
11	Disparities in the appropriateness of medication use: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) population-based cohort study. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1702-1710.	3.0	6
12	Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study. <i>Clinical Therapeutics</i> , 2019, 41, 1128-1138.e8.	2.5	4
13	Impact of eHealth on medication adherence among patients with asthma: A systematic review and meta-analysis. <i>Respiratory Medicine</i> , 2019, 149, 59-68.	2.9	83
14	Continuity of medication management among adults with schizophrenia and comorbid cardiometabolic conditions. <i>Journal of Pharmaceutical Health Services Research</i> , 2018, 9, 13-20.	0.6	6
15	Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs. <i>Drug Safety</i> , 2018, 41, 363-376.	3.2	12
16	Authors' Reply to Courtney Suggs and Colleaguesâ€™ Comment on: "Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs" • <i>Drug Safety</i> , 2018, 41, 1423-1424.	3.2	1
17	Does public perception bias lead to more frequent reporting of adverse events: branded vs generic drugs. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 753-756.	2.4	3
18	Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS). <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 93-102.	0.9	23

#	ARTICLE	IF	CITATIONS
19	Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs. <i>Pharmacotherapy</i> , 2017, 37, 429-437.	2.6	19
20	Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). <i>Expert Opinion on Drug Safety</i> , 2017, 16, 761-767.	2.4	112
21	Continuity of medication management in Medicaid patients with chronic comorbid conditions: An examination by mental health status. <i>General Hospital Psychiatry</i> , 2017, 45, 25-31.	2.4	4
22	Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS). <i>Clinical Drug Investigation</i> , 2017, 37, 1143-1152.	2.2	11
23	Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). <i>Epilepsy Research</i> , 2017, 135, 71-78.	1.6	19
24	Patterns of psychiatric emergency department utilization among community-dwelling Medicare beneficiaries under 65.. <i>Psychological Services</i> , 2017, 14, 387-396.	1.5	4
25	Disseminating Comparative Effectiveness Research Through Community-based Experiential Learning. <i>American Journal of Pharmaceutical Education</i> , 2017, 81, 9.	2.1	3
26	Patterns of treatment modifications among newly treated hypertensive patients. <i>Journal of Hypertension</i> , 2016, 34, 548-557.	0.5	2
27	Achieving Adherence After First-Line Antihypertensive Treatment: Should Fixed-Dose Combinations Receive Priority?. <i>Journal of Clinical Hypertension</i> , 2016, 18, 934-941.	2.0	4
28	Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. <i>Arthritis Care and Research</i> , 2016, 68, 1078-1088.	3.4	24
29	Antidepressant Medication Use and Its Association With Cardiovascular Disease and All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>Annals of Pharmacotherapy</i> , 2016, 50, 253-261.	1.9	25
30	Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs. <i>Clinical Drug Investigation</i> , 2016, 36, 281-292.	2.2	11
31	Prescriber Continuity and Medication Adherence for Complex Patients. <i>Annals of Pharmacotherapy</i> , 2015, 49, 293-302.	1.9	51
32	Factors associated with psychotropic prescriptions, psychiatric hospitalization, and spending among Medicare beneficiaries under 65. <i>Disability and Health Journal</i> , 2015, 8, 424-433.	2.8	4
33	Treatment patterns among breast cancer patients in the United States using two national surveys on visits to physicians' offices and hospital outpatient departments. <i>Research in Social and Administrative Pharmacy</i> , 2015, 11, 708-720.	3.0	7
34	Utilization Patterns of Antihypertensive Drugs Among the Chronic Kidney Disease Population in the United States: A Cross-sectional Analysis of the National Health and Nutrition Examination Survey. <i>Clinical Therapeutics</i> , 2015, 37, 188-196.	2.5	9
35	The Intersection of Patient Complexity, Prescriber Continuity and Acute Care Utilization. <i>Journal of General Internal Medicine</i> , 2014, 29, 594-601.	2.6	36
36	Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis. <i>Drug Safety</i> , 2014, 37, 19-31.	3.2	119

#	ARTICLE	IF	CITATIONS
37	Tumor Necrosis Factor- α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study. <i>Journal of Rheumatology</i> , 2014, 41, 2129-2136.	2.0	28
38	Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis. <i>CNS Drugs</i> , 2014, 28, 699-712.	5.9	18
39	Expert panel assessment of acute liver injury identification in observational data. <i>Research in Social and Administrative Pharmacy</i> , 2014, 10, 156-167.	3.0	7
40	Prevalence of depressive symptoms and predictors of treatment among U.S. adults from 2005 to 2010. <i>General Hospital Psychiatry</i> , 2014, 36, 330-336.	2.4	72
41	Enhancing Quality in Psychiatry with Psychiatrists (EQUIPP)â€”Results from a Pilot Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 884-888.	1.2	4
42	Exploration of heterogeneity in distributed research network drug safety analyses. <i>Research Synthesis Methods</i> , 2014, 5, 352-370.	8.7	5
43	Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 477-489.	2.2	256
44	Exploratory Evaluation of Medication Classes Most Commonly Involved in Nursing Home Errors. <i>Journal of the American Medical Directors Association</i> , 2013, 14, 403-408.	2.5	25
45	How Well Do Various Health Outcome Definitions Identify Appropriate Cases in Observational Studies?. <i>Drug Safety</i> , 2013, 36, 27-32.	3.2	17
46	Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record. <i>BMC Endocrine Disorders</i> , 2013, 13, 24.	2.2	7
47	Analgesic Medication Errors in North Carolina Nursing Homes. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2013, 27, 125-131.	0.8	10
48	Developing an expert panel process to refine health outcome definitions in observational data. <i>Journal of Biomedical Informatics</i> , 2013, 46, 795-804.	4.3	10
49	Confounding control in a nonexperimental study of STAR*D data: logistic regression balanced covariates better than boosted CART. <i>Annals of Epidemiology</i> , 2013, 23, 204-209.	1.9	5
50	Systematic Review of Biliary Atresia Services. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 57, e19-20.	1.8	0
51	Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STAR*D trial data. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 138-144.	1.9	13
52	Performance of Medometer visual tool for measuring medication adherence and comparison with other measures. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2013, 53, 198-205.	1.5	6
53	Treating Depression After Initial Treatment Failure. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 114-119.	1.4	69
54	Treatment Use and Costs Among Privately Insured Youths With Diagnoses of Bipolar Disorder. <i>Psychiatric Services</i> , 2012, 63, 1019-1025.	2.0	16

#	ARTICLE	IF	CITATIONS
55	Adherence to Antipsychotics and Cardiometabolic Medication: Association With Health Care Utilization and Costs. <i>Psychiatric Services</i> , 2012, 63, 920-928.	2.0	31
56	Paediatric <i>Helicobacter pylori</i> Practice in the United Kingdom. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 339-339.	1.8	1
57	Prevalence of Bipolar Disorder Diagnoses and Psychotropic Drug Therapy Among Privately Insured Children and Adolescents. <i>Pharmacotherapy</i> , 2012, 32, 1085-1094.	2.6	15
58	Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 93.	1.7	65
59	Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1491-1505.	1.9	15
60	How Should Primary Care Doctors Select Which Antidepressants to Administer?. <i>Current Psychiatry Reports</i> , 2012, 14, 360-369.	4.5	22
61	Statins are associated with reduced use of steroids in inflammatory bowel disease: A retrospective cohort study*. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1048-1056.	1.9	61
62	COMPARATIVE EFFECTIVENESS OF SECOND-GENERATION ANTIDEPRESSANTS FOR ACCOMPANYING ANXIETY, INSOMNIA, AND PAIN IN DEPRESSED PATIENTS: A SYSTEMATIC REVIEW. <i>Depression and Anxiety</i> , 2012, 29, 495-505.	4.1	50
63	Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. <i>General Hospital Psychiatry</i> , 2012, 34, 192-200.	2.4	11
64	Antipsychotic Adherence and Its Correlation to Health Outcomes for Chronic Comorbid Conditions. <i>primary care companion for CNS disorders, The</i> , 2012, 14, .	0.6	13
65	Medication Errors During Patient Transitions into Nursing Homes: Characteristics and Association With Patient Harm. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 413-422.	3.0	32
66	Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?. <i>Depression and Anxiety</i> , 2011, 28, 989-998.	4.1	12
67	Online Medication Error Graphic Reports. <i>Journal of Patient Safety</i> , 2011, 7, 92-98.	1.7	2
68	Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 125-130.	0.9	28
69	Part D Plan Enrollment by Uninsured Medicare Beneficiaries. <i>Medical Care</i> , 2010, 48, 183-186.	2.4	8
70	A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the united states from 2003 to 2005. <i>Clinical Therapeutics</i> , 2010, 32, 1308-1319.	2.5	58
71	Guideline-concordant antidepressant use among patients with major depressive disorder. <i>General Hospital Psychiatry</i> , 2010, 32, 360-367.	2.4	19
72	Prescription refill records as a screening tool to identify antidepressant non-adherence. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 33-37.	1.9	38

#	ARTICLE	IF	CITATIONS
73	Risk of hyperkalemia associated with selective COX-2 inhibitors. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1194-1198.	1.9	15
74	Patterns in nursing home medication errors: disproportionality analysis as a novel method to identify quality improvement opportunities. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1087-1094.	1.9	11
75	Repeat medication errors in nursing homes: Contributing factors and their association with patient harm. <i>American Journal of Geriatric Pharmacotherapy</i> , 2010, 8, 258-270.	3.0	38
76	Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug & Effectiveness Review Project. <i>Biologics: Targets and Therapy</i> , 2009, , 485.	3.2	4
77	Inadequate reporting of trials compromises the applicability of systematic reviews. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 323-330.	0.5	9
78	Controlling for Drug Dose in Systematic Review and Meta-Analysis: A Case Study of the Effect of Antidepressant Dose. <i>Medical Decision Making</i> , 2009, 29, 91-103.	2.4	41
79	Are some antidepressants better than others?. <i>Nature Reviews Neurology</i> , 2009, 5, 239-240.	10.1	4
80	Adherence: Comparison of Methods to Assess Medication Adherence and Classify Nonadherence. <i>Annals of Pharmacotherapy</i> , 2009, 43, 413-422.	1.9	244
81	Predialysis chronic kidney disease: Evaluation of quality of life in clinic patients receiving comprehensive anemia care. <i>Research in Social and Administrative Pharmacy</i> , 2009, 5, 143-153.	3.0	17
82	Effect of Ropinirole on Sleep Outcomes in Patients with Restless Legs Syndrome: Meta-Analysis of Pooled Individual Patient Data from Randomized Controlled Trials. <i>Pharmacotherapy</i> , 2009, 29, 255-262.	2.6	25
83	Methodology of a pilot study to improve the quality of medication use in older adults: Enhancing quality in psychiatry using pharmacists (EQUIPP). <i>American Journal of Geriatric Pharmacotherapy</i> , 2009, 7, 362-372.	3.0	9
84	Direct-to-Consumer and Physician Promotion of Tegaserod Correlated With Physician Visits, Diagnoses, and Prescriptions. <i>Gastroenterology</i> , 2009, 137, 518-524.e2.	1.3	31
85	The General and Comparative Efficacy and Safety of Duloxetine in Major Depressive Disorder. <i>Drug Safety</i> , 2009, 32, 1159-1173.	3.2	32
86	Ranking antidepressants. <i>Lancet, The</i> , 2009, 373, 1761.	13.7	8
87	Depression affects adherence measurement but not the effectiveness of an adherence intervention in heart failure patients. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2009, 49, 760-768.	1.5	25
88	Risk of Adverse Gastrointestinal Events from Inhaled Corticosteroids. <i>Pharmacotherapy</i> , 2008, 28, 1325-1334.	2.6	16
89	Comparative Risk for Harms of Second-Generation Antidepressants. <i>Drug Safety</i> , 2008, 31, 851-865.	3.2	118
90	Treating the Physical Symptoms of Depression With Second-Generation Antidepressants: A Systematic Review and Metaanalysis. <i>Psychosomatics</i> , 2008, 49, 191-198.	2.5	29

#	ARTICLE	IF	CITATIONS
91	Efficacy and tolerability of second-generation antidepressants in social anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2008, 23, 170-179.	1.7	25
92	Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants. <i>Psychiatric Services</i> , 2008, 59, 1121-1130.	2.0	67
93	Preventing medication errors in long-term care: results and evaluation of a large scale web-based error reporting system. <i>Quality and Safety in Health Care</i> , 2007, 16, 297-302.	2.5	60
94	Authors' reply to comment on: a simple and valid tool distinguished efficacy from effectiveness studies. <i>Journal of Clinical Epidemiology</i> , 2007, 60, 755.	5.0	2
95	Functional Outcomes of Drug Treatment in Alzheimer's Disease. <i>Drugs and Aging</i> , 2007, 24, 155-167.	2.7	72
96	Serious Adverse Events With Infliximab: Analysis of Spontaneously Reported Adverse Events. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 729-735.e1.	4.4	97
97	Effect of Second-Generation Antidepressants on Mania- and Depression-Related Visits in Adults with Bipolar Disorder: A Retrospective Study. <i>Value in Health</i> , 2007, 10, 128-136.	0.3	9
98	Geographic Information System mapping as a tool to assess nonresponse bias in survey research. <i>Research in Social and Administrative Pharmacy</i> , 2007, 3, 249-264.	3.0	7
99	Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. <i>Clinical Rheumatology</i> , 2007, 27, 67-76.	2.2	68
100	The Burden of Gastrointestinal and Liver Diseases, 2006. <i>American Journal of Gastroenterology</i> , 2006, 101, 2128-2138.	0.4	577
101	A simple and valid tool distinguished efficacy from effectiveness studies. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 1040-1048.	5.0	176
102	Types of medication errors in north carolina nursing homes: A target for quality improvement. <i>American Journal of Geriatric Pharmacotherapy</i> , 2006, 4, 52-61.	3.0	43
103	Second-generation antidepressant discontinuation and depressive relapse in adult patients with bipolar depression: Results of a retrospective database analysis. <i>Clinical Therapeutics</i> , 2006, 28, 979-989.	2.5	9
104	Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes. <i>Annals of Family Medicine</i> , 2006, 4, 253-262.	1.9	116
105	Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. <i>International Clinical Psychopharmacology</i> , 2005, 20, 59-69.	1.7	48
106	The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 139-157.	3.0	12
107	Methodological challenges surrounding direct-to-consumer advertising research: The measurement conundrum. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 331-347.	3.0	13
108	The study of direct-to-consumer advertising for prescription drugs. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 348-368.	3.0	5

#	ARTICLE	IF	CITATIONS
109	Distinguishing characteristics of patients who seek more information or request a prescription in response to direct-to-consumer advertisements†. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 231-250.	3.0	15
110	Factors associated with potentially inappropriate drug utilization in a sample of rural community-dwelling older adults. <i>American Journal of Geriatric Pharmacotherapy</i> , 2005, 3, 168-179.	3.0	43
111	Osteoporosis beliefs and antiresorptive medication use. <i>Maturitas</i> , 2005, 50, 196-208.	2.4	36
112	Factors influencing the shift of patients from one proton pump inhibitor to another: The effect of direct-to-consumer advertising. <i>Clinical Therapeutics</i> , 2005, 27, 1478-1487.	2.5	26